Completed PHASE3 INTERVENTIONAL 2-arm NCT02616783

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

A Phase 3b, Randomized, Open-Label Study to Evaluate Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years

Sponsor: Gilead Sciences

Conditions HIV-1 Infection

Interventions 3TC E/C/F/TAF FTC FTC/TDF TDF Third agent

Updated 13 times since 2017 Last updated: Feb 18, 2020 Started: Dec 22, 2015 Primary completion: Feb 21, 2018 Completion: Mar 21, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates HIV-1 Infection and is currently completed. Gilead Sciences leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

13 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Apr 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 8 earlier versions

Mar 2019 — Apr 2020 [monthly]

Completed PHASE3
Nov 2018 — Mar 2019 [monthly]

Completed PHASE3
Jun 2018 — Nov 2018 [monthly]

Completed PHASE3
May 2018 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Mar 2018 — May 2018 [monthly]

Active Not Recruiting PHASE3
May 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Feb 2017 — May 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gilead Sciences

Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Belfast, United Kingdom , Bergamo, Italy , Bordeaux, France , Brussels, Belgium , Busto Arsizio, Italy , Dijon, France , Genova, Italy , Ghent, Belgium , London, United Kingdom and 16 more locations